🇺🇸 aminolevulinic acid (ALA) in United States
8 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 8
Most-reported reactions
- Oesophageal Stenosis — 5 reports (62.5%)
- Neuropathy — 1 report (12.5%)
- Oesophageal Perforation — 1 report (12.5%)
- Porphyria — 1 report (12.5%)
Other Oncology approved in United States
Frequently asked questions
Is aminolevulinic acid (ALA) approved in United States?
aminolevulinic acid (ALA) does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for aminolevulinic acid (ALA) in United States?
University of California, Davis is the originator. The local marketing authorisation holder may differ — check the official source linked above.